BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 16164488)

  • 1. Use of moxonidine in elderly patients with resistant hypertension.
    Martin U; Hill C; O' Mahony D
    J Clin Pharm Ther; 2005 Oct; 30(5):433-7. PubMed ID: 16164488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"].
    Amado P; Vasconcelos N; Santos I; Almeida L; Nazaré J; Carmona J
    Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and tolerability of the perindopril/indapamide combination therapy for hypertension: the PRIMUS study.
    Holzgreve H; Risler T; Trenkwalder P
    Curr Med Res Opin; 2006 Sep; 22(9):1849-58. PubMed ID: 16968588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study.
    Lacourcière Y; Wright JT; Samuel R; Zappe D; Purkayastha D; Black HR;
    Blood Press Monit; 2009 Jun; 14(3):112-20. PubMed ID: 19384192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension.
    Teitelbaum I; Chilvers M; Reiz RJ
    Can J Cardiol; 2004 Oct; 20 Suppl C():11C-16C. PubMed ID: 16807618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective imidazoline agonist moxonidine in obese hypertensive patients.
    Sanjuliani AF; de Abreu VG; Francischetti EA
    Int J Clin Pract; 2006 May; 60(5):621-9. PubMed ID: 16700870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of the alpha1-blocker doxazosin as a third-line antihypertensive drug.
    Ohta Y; Tsuchihashi T; Onaka U; Eto K; Ueno M
    Hypertens Res; 2007 Apr; 30(4):301-6. PubMed ID: 17541208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone excess and resistance to 24-h blood pressure control.
    Pimenta E; Gaddam KK; Pratt-Ubunama MN; Nishizaka MK; Cofield SS; Oparil S; Calhoun DA
    J Hypertens; 2007 Oct; 25(10):2131-7. PubMed ID: 17885558
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regular alcohol drinking is a determinant of masked morning hypertension detected by home blood pressure monitoring in medicated hypertensive patients with well-controlled clinic blood pressure: the Jichi Morning Hypertension Research (J-MORE) study.
    Ishikawa J; Kario K; Eguchi K; Morinari M; Hoshide S; Ishikawa S; Shimada K;
    Hypertens Res; 2006 Sep; 29(9):679-86. PubMed ID: 17249523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.
    Prichard BN; Owens CW; Graham BR
    J Hum Hypertens; 1997 Aug; 11 Suppl 1():S29-45. PubMed ID: 9321737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administration time-dependent effects of valsartan on ambulatory blood pressure in elderly hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; Mojón A; Rodríguez M; Chayán L; López JE; Fontao MJ; Soler R; Fernández JR
    Chronobiol Int; 2005; 22(4):755-76. PubMed ID: 16147905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy.
    Dolan E; Stanton AV; Thom S; Caulfield M; Atkins N; McInnes G; Collier D; Dicker P; O'Brien E;
    J Hypertens; 2009 Apr; 27(4):876-85. PubMed ID: 19516185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
    Haenni A; Lithell H
    J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of moxonidine in mild to moderate hypertension.
    Jain S; Malhotra P; Kumari S; Varma S
    J Assoc Physicians India; 2001 Aug; 49():829-30. PubMed ID: 11837474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension.
    Verdecchia P; Calvo C; Möckel V; Keeling L; Satlin A
    Blood Press; 2007; 16(6):381-91. PubMed ID: 18058456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.